XRAYS - Making Sense of Cancer Headlines

FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.

XRAYS logo and women

Read the topic that we reviewed this week

STUDY: Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

XRAYS Rating
XRAYS study

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19)

Search for reviews by category, keyword or date or browse our recent articles below

Featured Studies and Articles

XRAYS Rating

STUDY: LGBTQ patients recommend improvements for their cancer care

Little is known about the cancer care experiences of lesbian, gay, bisexual, transgender and queer (LGBTQ) patients. This study looks at recommendations from the LGBTQ community for improving their cancer care. (6/20/19)

XRAYS Rating

STUDY: New targeted therapy for early-stage HER2-positive breast cancer

The KATHERINE trial looked at the benefit of the new drug, Kadcyla, for treating early-stage breast cancer after surgery and chemotherapy. The results of this study led to FDA approval in May 2019. (6/17/19)

XRAYS Rating

STUDY: A low-fat diet may decrease postmenopausal breast cancer deaths

Research reported at the 2019 annual meeting of the American Society of Clinical Oncology establishes a link between dietary fat intake and its impact on postmenopausal women’s risk of dying from breast cancer. (6/13/19)

XRAYS Rating

ARTICLE: A young woman's story of genetic testing and risk-reducing mastectomy

Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)

Find older XRAYS studies and articles

By keyword search:

By date range:

FORCE:Facing Our Risk of Cancer Empowered